BP and USP MoU formalise partnership to strengthen quality of medicines and public health
The relationship between the British Pharmacopoeia (BP) and United States Pharmacopeia (USP) will be further strengthened following the signing of a Memorandum of Understanding (MoU) between the two parties in Washington D.C. on Friday.
The agreement will enable improved collaboration and knowledge sharing between the BP and the USP in a wide area of standards setting for medicines.
This collective working agreement supports the important role public quality standards play in ensuring the quality of medicines taken by patients every day.
One of the features of this agreement is the commitment from both organisations to provide opportunities for exchange of staff and participation in events and joint working.
The challenges of assuring medicines quality in a world of globalised supply chains and rapid technological developments are best met by working in partnership with the BP and USP’s global peers.
James Pound, Group Manager - British Pharmacopoeia & Laboratory Services at Medicines and Healthcare products Regulatory Agency (MHRA), said:
“The BP greatly values its relationships with our international partners.
“This agreement with the USP is a great development in our ability to work with a global peer on our shared mission to protect public health through public quality standards for medicines.
“The work we do will directly benefit from the knowledge sharing and collaboration that will result from this agreement. This will better enable us to serve the needs of our patients and stakeholders across the world and address the future challenges of assuring medicines quality.”
Dr. Jaap Venema, USP executive vice president and chief science officer, said:
“Modern innovations make this partnership essential to ensuring the quality of medicines.
“Our partnership helps both organisations develop standards that are used to protect the quality of the medicines patients worldwide take each and every day.”
USP is an independent scientific organization that collaborates with the world’s top experts in health and science to develop quality standards for medicines, dietary supplements, and food ingredients. Through our standards, advocacy and education, USP helps increase the availability of quality medicines, supplements and food for billions of people worldwide. For more information about USP, visit www.usp.org
The British Pharmacopoeia is a book of published and publicly available standards for pharmaceutical ingredients and finished medicinal products. It is prepared and published annually by the British Pharmacopoeia Commission, secretariat of the Medicines and Healthcare products Regulatory Agency of the United Kingdom and is the only comprehensive collection of official standards for medicinal products. It provides an authoritative statement of quality that a medicinal product is expected to meet during its period of use to the end of its shelf-life.
Notes to Editor
1. MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. Underpinning all our work lies robust and fact-based judgements to ensure that the benefits justify any risks. The MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). The MHRA is an executive agency of the Department of Health.
2. The value of pharmacopoeial standards – These standards enable users to make an objective assessment in relation to the quality of a material. Where necessary these are supported by physical standards. Quality is critical to ensuring the safety and efficacy of medicines taken by patients every day. Pharmacopoeial quality standards are one of the foundations of ensuring acceptable quality alongside good practice quality guidelines and regulations and regulatory assessment.